Friday, July 17, 2026 | 6:45 – 7:45 AM EDT
Palais des congrès de Montréal
Room 510B
Montréal, Quebec, H2Z 1H2
Sharper Focus on Geographic Atrophy
Join us for a Picture This Symposium! | Sharper Focus on Geographic Atrophy
This symposium is an interactive symposium that gives retina specialists and the broader ophthalmology care team a practical, imaging-based playbook for catching geographic atrophy (GA) earlier and managing it with confidence. Expect dynamic pathophysiology animations, real-world cases, live Q&A, and takeaways you can put to work right away. Bring GA into sharper focus.
Sharpen Your GA Approach — Register Today!
Meet Our Faculty
Arshad M. Khanani MD, MA, FASRS
Managing Partner, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates
Reno, NV, USA
Glenn J. Jaffe, MD
Chief of the Vitreoretinal Division at Duke Eye Center
Durham, NC, USA
In-Person & Virtual Registration
In-Person Attendees Must Be Registered for ASRS 2026
To attend in person, you must be registered as an ASRS attendee. If you can’t join in-person, this session is also available FREE via livestream on our social channels or Zoom. Virtual participants can still earn credit, but will need to register below to receive instructions for streaming links & claiming credit.
This activity is designed for retina specialists and other members of the interprofessional and multidisciplinary team involved in the management of geographic atrophy in the U.S.
After completing this activity, the participant should be better able to:
Assess clinical and multimodal imaging features that differentiate early and intermediate age-related macular degeneration (AMD) from geographic atrophy (GA)
Analyze the role of the complement system in GA pathogenesis and the mechanism of action of complement-targeted therapies
Select appropriate candidates for complement inhibitor therapy and integrate these agents into evidence-based care pathways for patients with GA secondary to AMD
Implement structured, evidence-based monitoring strategies to track GA progression and guide patient care
This activity is provided by MLI
Accreditation, Support and Credit
In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute Inc (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 0.5 contact hour in the area of pharmacology.
PA
Medical Learning Institute Inc has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Optometrist Continuing Education
Medical Learning Institute Inc designates this synchronous in-person activity for a maximum of 1.0 COPE credit hour.
Support Statement
This activity is supported by educational grants from Astellas Pharma US, Inc. and Apellis, a subsidiary of Biogen.
Medical Learning Institute Inc is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.
To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education.
All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Planner/Presenter
Arshad M. Khanani MD, MA, FASRS, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: AbbVie, ADARx Pharmaceuticals, Adverum, Alcon, Alkeus, Allgenesis, Amgen, Annexin, Annexon, Apellis Pharmaceuticals, Ashvattha Therapeutics, Astellas, Aviceda Therapeutics, Beacon Therapeutics, Boehringer Ingelheim, Clearside Biomedical, Complement Therapeutics, Entrada, Exegenesis, EyePoint Pharmaceuticals, 4DMT, Frontera Therapeutics, Genentech, Harrow, i-Lumen Scientific, InFocus, Iveric Bio, Janssen Pharmaceuticals, Kriya Therapeutics, Kyowa Kirin, Lexitas, Merit, Nanoscope, Neurotech, Novartis, Ocugen, Ocular Therapeutix, Oculis, Ollin, Opthea, Opus Genetics, Perfuse, PolyPhotonix, Recens Medical, Regeneron Pharmaceuticals, Regenxbio, Revive, RevOpsis, Roche, Samsung, Sanofi, Stealth Bio Therapeutics, Sun Pharma, Surrozen, Théa Pharma, Therini, Unity Biotechnology, Vanotech, Vial, ZipBio
Research Funding/Support: Adverum, Alexion, Annexon, Astellas, Aviceda Therapeutics, Biojiva, Boehringer Ingelheim, Complement Therapeutics, Exegenesis, Eyepoint Pharmaceuticals, 4DMT, Genentech, Gyroscope Therapeutics, Iveric Bio, Janssen, Kyowa Kirin, Ocular Therapeutix, Ollin, ONL, Regenxbio, Roche, Sanofi, Vanotech
Other: Stock Options: Ashvattha, Aviceda Therapeutics, Oculis, Ollin, Perfuse, PolyPhotonix, Recens Medical, RevOpsis, Vial, ZipBio
Planner/Presenter
Glenn J. Jaffe, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Alcon, Annexon, Apellis, Character Bio, EyePoint Pharmaceuticals, Kriya, Novartis, Ocular Therapeutix, Regeneron, Roche/Genentech
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute Inc, the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity, however, registration is required. In order to receive credit, learners must participate in the entire CE activity, complete the activity evaluation form and your certificate of credit will be generated. You will receive your certificate from Medical Learning Institute Inc.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact MLI at mvu@mlieducation.org.
About This Activity
Medical Learning Institute Inc is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc or any of its partners, providers, and/or supporters.
Copyright © 2026 Medical Learning Institute Inc. All Rights Reserved.
This activity is supported by educational grants from Astellas Pharma US, Inc. and Apellis, a subsidiary of Biogen.
This program is not affiliated with or endorsed by the ASRS